Aleix Prat

List of Publications by Citations

287 papers	23,302 citations	62 h-index	151 g-index
334 ext. papers	28,963 ext. citations	7.7 avg, IF	7.92 L-index

#	Paper	IF	Citations
287	Comprehensive molecular portraits of human breast tumours. *Nature*, **2012**, 490, 61-70	50.4	8025
286	Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. *Breast Cancer Research*, **2010**, 12, R68	8.3	1428
285	Deconstructing the molecular portraits of breast cancer. *Molecular Oncology*, **2011**, 5, 5-23	7.9	841
284	4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)□ *Annals of Oncology*, **2018**, 29, 1634-1657	10.3	645
283	Clinical implications of the intrinsic molecular subtypes of breast cancer. *Breast*, **2015**, 24 Suppl 2, S26-35	3.6	450
282	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. *Cell Reports*, **2013**, 4, 1116-30	10.6	447
281	PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. *Cancer Discovery*, **2012**, 2, 1036-47	24.4	418
280	Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. *Journal of Clinical Oncology*, **2011**, 29, 2342-9	2.2	379
279	Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. *Journal of Clinical Oncology*, **2013**, 31, 203-9	2.2	376
278	Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. *Oncologist*, **2013**, 18, 123-33	5.7	376
277	A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. *Cancer Research*, **2013**, 73, 4885-97	10.1	331
276	5th ESO-ESMO international consensus guidelines for advanced breast□cancer (ABC 5). *Annals of Oncology*, **2020**, 31, 1623-1649	10.3	282
275	USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. *Nature Medicine*, **2012**, 18, 429-35	50.5	280
274	Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. *Annals of Oncology*, **2014**, 25, 552-563	10.3	242
273	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 3761-6	11.5	241
272	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. *Cancer Research*, **2017**, 77, 3540-3550	10.1	213
271	Practical implications of gene-expression-based assays for breast oncologists. *Nature Reviews Clinical Oncology*, **2011**, 9, 48-57	19.4	205

270	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. *Science Translational Medicine*, **2015**, 7, 283ra51	17.5	204
269	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. *BMC Medical Genomics*, **2012**, 5, 44	3.7	199
268	MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. *Nature Communications*, **2013**, 4, 1393	17.4	184
267	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. *Lancet Oncology, The*, **2017**, 18, 545-554	21.7	175
266	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. *Breast Cancer Research and Treatment*, **2012**, 132, 523-35	4.4	165
265	Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. *Journal of Clinical Investigation*, **2012**, 122, 1541-52	15.9	161
264	Defining the cellular precursors to human breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 2772-7	11.5	160
263	Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. *Bioinformatics*, **2016**, 32, 1097-9	7.2	150
262	Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. *Clinical Cancer Research*, **2014**, 20, 511-21	12.9	143
261	How many etiological subtypes of breast cancer: two, three, four, or more?. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	142
260	The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. *Nature Clinical Practice Oncology*, **2008**, 5, 531-42		136
259	Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. *Breast Cancer Research and Treatment*, **2013**, 142, 237-55	4.4	132
258	Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	132
257	PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. *Breast Cancer Research and Treatment*, **2012**, 135, 301-6	4.4	117
256	Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. *Clinical Cancer Research*, **2016**, 22, 644-56	12.9	114
255	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. *Cancer Research*, **2017**, 77, 2213-2221	10.1	109
254	The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. *Cell Reports*, **2014**, 6, 1059-1072	10.6	109
253	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. *Lancet Respiratory Medicine,the*, **2018**, 6, 771-781	35.1	107

252	Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. *BMC Medical Genomics*, **2011**, 4, 3	3.7	104
251	Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. *Annals of Oncology*, **2012**, 23, 2866-2873	10.3	103
250	Defining breast cancer intrinsic subtypes by quantitative receptor expression. *Oncologist*, **2015**, 20, 474-82	5.7	102
249	Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. *Cancer Discovery*, **2020**,	24.4	96
248	Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. *Cancer Cell*, **2012**, 21, 626-641	24.3	92
247	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. *BMC Medicine*, **2015**, 13, 303	11.4	87
246	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. *Journal of Clinical Investigation*, **2013**, 123, 2551-63	15.9	86
245	Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. *Oncologist*, **2014**, 19, 1076-83	5.7	85
244	MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. *Cell Stem Cell*, **2011**, 8, 525-37	18	84
243	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. *British Journal of Cancer*, **2014**, 111, 1532-41	8.7	82
242	MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. *Breast Cancer Research and Treatment*, **2013**, 137, 373-82	4.4	80
241	miR-206 Inhibits Stemness and Metastasis of Breast Cancer by Targeting MKL1/IL11 Pathway. *Clinical Cancer Research*, **2017**, 23, 1091-1103	12.9	79
240	Clinical implementation of the intrinsic subtypes of breast cancer. *Lancet Oncology, The*, **2010**, 11, 718-9; author reply 720-1	21.7	79
239	PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. *Breast Cancer Research and Treatment*, **2013**, 138, 457-66	4.4	78
238	Molecular classification of triple-negative tumors. *Breast Cancer Research*, **2011**, 13,	8.3	78
237	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. *Journal of Clinical Investigation*, **2014**, 124, 1418-1418	15.9	78
236	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. *Clinical Cancer Research*, **2017**, 23, 649-657	12.9	75
235	MSK1 regulates luminal cell differentiation and metastatic dormancy in ER breast cancer. *Nature Cell Biology*, **2018**, 20, 211-221	23.4	71

234	Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation. *Stem Cell Reports*, **2014**, 2, 633-47	8	69
233	Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. *Head and Neck*, **2008**, 30, 680-3	4.2	69
232	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. *Lancet Oncology, The*, **2019**, 20, 1360-1369	21.7	68
231	Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. *Annals of Oncology*, **2016**, 27, 1867-73	10.3	68
230	Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. *JAMA Oncology*, **2016**, 2, 1287-1294	13.4	65
229	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. *Lancet Oncology, The*, **2021**, 22, 212-222	21.7	64
228	A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. *Clinical Cancer Research*, **2013**, 19, 6787-801	12.9	63
227	Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. *Breast Cancer Research*, **2011**, 13, R125	8.3	63
226	Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis. *Journal of the National Cancer Institute*, **2015**, 107, djv256	9.7	60
225	SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. *Oncogene*, **2015**, 34, 671-80	9.2	58
224	Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E1301-10	11.5	58
223	Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. *Clinical Cancer Research*, **2016**, 22, 560-6	12.9	57
222	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. *Breast Cancer Research*, **2020**, 22, 45	8.3	55
221	Update on novel therapeutic agents for cervical cancer. *Gynecologic Oncology*, **2008**, 110, S72-6	4.9	54
220	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. *Npj Breast Cancer*, **2021**, 7, 1	7.8	54
219	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. *Stem Cell Reports*, **2017**, 8, 1392-1407	8	53
218	Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. *British Journal of Cancer*, **2012**, 107, 1249-56	8.7	53
217	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. *Lancet Oncology, The*, **2020**, 21, 33-43	21.7	52

216	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). *Clinical Cancer Research*, **2019**, 25, 2975-2987	12.9	51
215	Predicting drug responsiveness in human cancers using genetically engineered mice. *Clinical Cancer Research*, **2013**, 19, 4889-99	12.9	51
214	TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer. *European Urology*, **2016**, 70, 709-713	10.2	48
213	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. *Breast Cancer Research and Treatment*, **2014**, 146, 557-66	4.4	48
212	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. *Journal of the National Cancer Institute*, **2020**, 112, 46-54	9.7	48
211	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. *Clinical Cancer Research*, **2018**, 24, 5820-5829	12.9	47
210	The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 221-6	11.5	47
209	A rare case of malignant solitary fibrous tumor of the spinal cord. *Spine*, **2008**, 33, E397-9	3.3	47
208	New approaches in angiogenic targeting for colorectal cancer. *World Journal of Gastroenterology*, **2007**, 13, 5857-66	5.6	46
207	Identification of , , and Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients. *Clinical Chemistry*, **2017**, 63, 751-760	5.5	45
206	A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. *Annals of Oncology*, **2018**, 29, 170-177	10.3	45
205	Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. *Cancer Treatment Reviews*, **2018**, 67, 63-70	14.4	45
204	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. *Annals of Oncology*, **2021**, 32, 1216-1235	10.3	44
203	Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer. *British Journal of Cancer*, **2017**, 117, 1777-1786	8.7	43
202	Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. *Annals of Oncology*, **2008**, 19, 327-31	10.3	43
201	ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. *Journal of Clinical Investigation*, **2013**, 123, 4329-43	15.9	43
200	Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. *Scientific Reports*, **2013**, 3, 3544	4.9	42
199	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. *Annals of Oncology*, **2018**, 29, 2121-2128	10.3	41

198	GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. *Cell Reports*, **2017**, 21, 2183-2197	10.6	41
197	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. *Journal of Clinical Investigation*, **2018**, 128, 3887-3905	15.9	41
196	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer **2019**, 7, 90		40
195	SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling. *Molecular and Cellular Biology*, **2013**, 33, 3011-25	4.8	40
194	Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. *Cancers*, **2020**, 12,	6.6	40
193	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. *Cancer Treatment Reviews*, **2020**, 84, 101965	14.4	39
192	Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. *Clinical and Experimental Metastasis*, **2014**, 31, 33-45	4.7	38
191	De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. *Annals of Oncology*, **2019**, 30, 921-926	10.3	38
190	Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. *BMC Cancer*, **2014**, 14, 302	4.8	37
189	Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. *Lancet Oncology, The*, **2021**, 22, 489-498	21.7	37
188	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. *Nature Communications*, **2020**, 11, 385	17.4	36
187	Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. *Breast Cancer Research and Treatment*, **2016**, 156, 81-9	4.4	35
186	De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. *Breast*, **2017**, 34 Suppl 1, S19-S26	3.6	35
185	Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. *Molecular Oncology*, **2014**, 8, 20-6	7.9	34
184	Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. *Breast Cancer Research and Treatment*, **2014**, 147, 185-91	4.4	33
183	Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. *BMC Medical Genomics*, **2011**, 4, 77	3.7	33
182	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.. *Journal of Clinical Oncology*, **2020**, 38, 1006-1006	2.2	32
181	Vasculitic neuropathy induced by pembrolizumab. *Annals of Oncology*, **2017**, 28, 433-434	10.3	30

180	Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	30
179	Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. *Cancer Research*, **2014**, 74, 7406-17	10.1	30
178	Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. *Annals of Oncology*, **2009**, 20, 294-7	10.3	27
177	Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer. *Current Medical Research and Opinion*, **2015**, 31, 1129-37	2.5	25
176	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. *Journal of the National Cancer Institute*, **2020**, 112, 1089-1097	9.7	25
175	Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast. *Molecular Oncology*, **2015**, 9, 1081-90	7.9	25
174	A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. *Annals of Oncology*, **2019** , 30, 927-933	10.3	22
173	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. *Breast Cancer Research*, **2020**, 22, 120	8.3	22
172	SEOM clinical guidelines in early stage breast cancer (2018). *Clinical and Translational Oncology*, **2019**, 21, 18-30	3.6	22
171	DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.. *Journal of Clinical Oncology*, **2020**	2.2	21
170	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. *Lancet Oncology, The*, **2021**, 22, 1669-1680	21.7	20
169	Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. *Oncotarget*, **2015**, 6, 28173-82	3.3	20
168	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. *Lancet Oncology, The*, **2020**, 21, 1455-1464	21.7	20
167	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. *Clinical Cancer Research*, **2020**, 26, 738-745	12.9	19
166	Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.. *Journal of Clinical Oncology*, **2020**, 38, 503-503	2.2	18
165	Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. *Clinical and Translational Oncology*, **2017**, 19, 119-124	3.6	17
164	A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. *Clinical Cancer Research*, **2017**, 23, 3035-3044	12.9	17
163	Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. *Breast Cancer Research and Treatment*, **2019**, 177, 103-114	4.4	17

162	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. *Clinical Cancer Research*, **2020**, 26, 5820-5829	12.9	17
161	Current and Future Management of HER2-Positive Metastatic Breast Cancer. *JCO Oncology Practice* , **2021**, 17, 594-604	2.3	17
160	Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial. *International Journal of Cancer*, **2020**, 146, 262-271	7.5	17
159	Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. *Lung Cancer*, **2009**, 66, 257-61	5.9	16
158	Predictive model of complexity in early palliative care: a cohort of advanced cancer patients (PALCOM study). *Supportive Care in Cancer*, **2018**, 26, 241-249	3.9	16
157	Coamplification of protects -amplified breast cancers from targeted therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E2594-E2603	11.5	15
156	Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials. *Acta Oncologica*, **2018**, 57, 38-43	3.2	15
155	FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. *Journal of Clinical Investigation*, **2020**, 130, 4871-4887	15.9	15
154	Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. *Journal of Clinical Oncology*, **2021**, 39, 1458-1467	2.2	15
153	Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial. *BMC Medicine*, **2019**, 17, 8	11.4	15
152	Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. *Clinical Cancer Research*, **2020**, 26, 4688-4698	12.9	14
151	Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection. *Clinical and Translational Oncology*, **2014**, 16, 386-94	3.6	14
150	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. *European Journal of Cancer*, **2021**, 150, 190-202	7.5	14
149	Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. *European Journal of Cancer*, **2019**, 120, 54-64	7.5	13
148	Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. *JAMA Oncology*, **2021**,	13.4	13
147	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. *European Journal of Cancer*, **2021**, 149, 134-152	7.5	13
146	What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?. *Clinical Cancer Research*, **2020**, 26, 2783-2788	12.9	12
145	The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. *Molecular Cancer Research*, **2019**, 17, 2063-2076	6.6	12

144	Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG.. *Journal of Clinical Oncology*, **2012**, 30, 1008-1008	2.2	12
143	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. *Oncologist*, **2019**, 24, 893-900	5.7	12
142	Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. *Breast Cancer Research*, **2019**, 21, 108	8.3	11
141	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score **2021**, 9,		11
140	Acute lung injury associated with docetaxel and bevacizumab. *Clinical Oncology*, **2007**, 19, 803-5	2.8	10
139	Abstract PD3-06: Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer (EBC) **2018**,		10
138	Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer. *Oncotarget*, **2017**, 8, 21930-21937	3.3	10
137	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. *Clinical Cancer Research*, **2020**, 26, 3720-3731	12.9	10
136	Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes: waiting for TAILORx and RxPONDER. *Annals of Oncology*, **2015**, 26, 70-74	10.3	9
135	Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy. **2009**,		9
134	Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma.. *Journal of Clinical Oncology*, **2015**, 33, 9069-9069	2.2	9
133	mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. *Cancers*, **2020**, 12,	6.6	9
132	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2021**, 1875, 188487	11.2	9
131	The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer. *International Journal of Cancer*, **2019**, 145, 1970-1981	7.5	8
130	Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC)? (GEICO 1205/NOVA TRIAL).. *Journal of Clinical Oncology*, **2017**, 35, 5508-5508	2.2	8
129	HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.. *Journal of Clinical Oncology*,	2.2	8
128	PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution. *Frontiers in Oncology*, **2019**, 9, 707	5.3	7
127	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. *Cells*, **2020**, 9,	7.9	7

126	Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis.. *Journal of Clinical Oncology*, **2011**, 29, 529-529	2.2	7
125	Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2 Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. *Clinical Cancer Research*, **2020**, 26, 5843-5851	12.9	7
124	Chemotherapy de-escalation using an F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. *Lancet Oncology, The*, **2021**, 22, 858-871	21.7	7
123	Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. *ESMO Open*, **2021**, 6, 100102	6	7
122	Chromosome 12p Amplification in Triple-Negative/Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. *Cancer Research*, **2019**, 79, 4258-4270	10.1	6
121	The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver. *Oncogene*, **2020**, 39, 5455-5467	9.2	6
120	Home management of acute medical complications in cancer patients: a prospective pilot study. *Supportive Care in Cancer*, **2016**, 24, 2129-2137	3.9	6
119	Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response. *European Journal of Radiology*, **2019**, 117, 132-139	4.7	6
118	PELO negatively regulates HER receptor signalling and metastasis. *Oncogene*, **2014**, 33, 1190-7	9.2	6
117	Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer. *Molecular Oncology*, **2021**, 15, 350-363	7.9	6
116	Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. *Molecular Oncology*, **2021**, 15, 887-900	7.9	6
115	Development and validation for research assessment of Oncotype DX Breast Recurrence Score, EndoPredict and Prosigna . *Npj Breast Cancer*, **2021**, 7, 15	7.8	6
114	Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx Digital Spatial Profiler. *Cancers*, **2021**, 13,	6.6	6
113	Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study. *Current Medical Research and Opinion*, **2016**, 32, 835-9	2.5	5
112	PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.. *Journal of Clinical Oncology*, **2019**, 37, 544-544	2.2	5
111	DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.. *Journal of Clinical Oncology*, **2019**, 37, TPS4588-TPS4588	2.2	5
110	Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. *Npj Precision Oncology*, **2021**, 5, 23	9.8	5
109	Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. *Journal of the National Cancer Institute*, **2021**,	9.7	5

108	SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. *Frontiers in Oncology* , **2021**, 11, 638482	5.3	5
107	Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial. *European Journal of Cancer*, **2021**, 148, 382-394	7.5	5
106	Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. *ESMO Open*, **2016**, 1, e000032	6	5
105	Dissecting the biological heterogeneity of HER2-positive breast cancer. *Breast*, **2021**, 59, 339-350	3.6	5
104	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. *Future Oncology*, **2020**, 16, 1801-1813	3.6	4
103	Prognostic role of CA-125 nadir in stage IV epithelial ovarian cancer. *Journal of Clinical Oncology*, **2008**, 26, 1771-2; author reply 1772	2.2	4
102	De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study.. *Journal of Clinical Oncology*, **2018**, 36, 507-507	2.2	4
101	SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer.. *Journal of Clinical Oncology*, **2018**, 36, TPS1101-TPS1101	2.2	4
100	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. *Journal of Clinical Oncology*, **2019**, 37, 571-571	2.2	4
99	On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.. *Journal of Clinical Oncology*, **2019**, 37, 574-574	2.2	4
98	Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. *Oncotarget*, **2016**, 7, 67956-67965	3.3	4
97	Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. *Frontiers in Oncology*, **2019**, 9, 1178	5.3	4
96	Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis.. *JCO Precision Oncology*, **2019**, 3, 1-6	3.6	4
95	Standardized versus research-based PAM50 intrinsic subtyping of breast cancer. *Clinical and Translational Oncology*, **2020**, 22, 953-955	3.6	4
94	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. *Breast Cancer Research*, **2021**, 23, 8	8.3	4
93	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. *Cancers*, **2021**, 13,	6.6	4
92	Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies. *Annals of Oncology*, **2018**, 29, viii61	10.3	4
91	Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. *European Journal of Cancer*, **2021**, 153, 133-141	7.5	4

90	Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?. *Cancer Treatment Reviews*, **2022**, 106, 102392	14.4	4
89	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. *Frontiers in Oncology*, **2019**, 9, 303	5.3	3
88	Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients. *Translational Research*, **2019**, 208, 73-84	11	3
87	PG 3.01 Clinical implications of the intrinsic molecular subtypes. *Breast*, **2015**, 24, S5-S6	3.6	3
86	PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial. *European Journal of Cancer*, **2018**, 92, S117-S118	7.5	3
85	Hepatic pneumatosis as a complication of an abdominal desmoid tumor. *Journal of Clinical Oncology*, **2007**, 25, 897-8	2.2	3
84	Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer **2018**,		3
83	Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.. *Journal of Clinical Oncology*, **2011**, 29, 502-502	2.2	3
82	Early safety from a phase 1, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected into liver tumors.. *Journal of Clinical Oncology*, **2018**, 36, 438-438	2.2	3
81	Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem).. *Journal of Clinical Oncology*, **2020**, 38, 3015-3015	2.2	3
80	A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.. *Journal of Clinical Oncology*, **2020**, 38, TPS1105-TPS1105	2.2	3
79	Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.. *EBioMedicine*, **2022**, 75, 103801	8.8	3
78	Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. *Cancers*, **2020**, 12,	6.6	3
77	RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. *Breast Cancer Research*, **2021**, 23, 42	8.3	3
76	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. *European Journal of Cancer*, **2021**, 148, 134-145	7.5	3
75	Gene expression profiles of breast cancer metastasis according to organ site. *Molecular Oncology*, **2021**,	7.9	3
74	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211042224	5.4	3
73	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. *Clinical Cancer Research*, **2021**, 27, 3116-3125	12.9	3

72	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. *EBioMedicine*, **2021**, 69, 103451	8.8	3
71	Molecular Tumor Boards. *Breast Care*, **2018**, 13, 141-143	2.4	2
70	Reply to Y.Yamamoto et al. *Journal of Clinical Oncology*, **2013**, 31, 2517-8	2.2	2
69	Acute severe hypothyroidism induced by sunitinib. *Radiotherapy and Oncology*, **2008**, 89, 124-5	5.3	2
68	Abstract P1-09-09: Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer **2017**,		2
67	Abstract P2-09-04: Association of intrinsic subtype and immune genes with pathological complete response in the OPTIHER-HEART phase II clinical trial following neoadjuvant trastuzumab/pertuzumab-based chemotherapy in HER2-positive breast cancer **2018**,		2
66	Gene expression-based predictors of chemotherapy response in basal-like breast cancer.. *Journal of Clinical Oncology*, **2012**, 30, 10500-10500	2.2	2
65	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. *Journal of*	2.2	2
64	Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial.. *Journal of Clinical Oncology*, **2018**, 36, 1056-1056	2.2	2
63	A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).. *Journal of Clinical Oncology*, **2018**, 36, TPS3105-TPS3105	2.2	2
62	A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC).. *Journal of Clinical Oncology*, **2020**, 38, 1011-1011	2.2	2
61	First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. *Frontiers in Oncology*, **2021**, 11, 744112	5.3	2
60	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 313	12.8	2
59	Biomarkers of immunotherapy response in breast cancer beyond PD-L1. *Breast Cancer Research and Treatment*, **2021**, 1	4.4	2
58	A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. *Clinical Cancer Research*, **2020**, 26, 6141-6148	12.9	2
57	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. *Npj Breast Cancer*, **2021**, 7, 73	7.8	2
56	Abstract OT-13-04: Solti-1716. Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK 4/6 inhibitor treatment (TATEN trial) **2021**,		2
55	Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. *Npj Breast Cancer*, **2021**, 7, 12	7.8	2

54	Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy. *Npj Breast Cancer*, **2021**, 7, 8	7.8	2
53	Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. *Frontiers in Oncology*, **2021**, 11, 710596	5.3	2
52	PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.. *Journal of Clinical Oncology*, **2015**, 33, TPS642-TPS642	2.2	1
51	Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.. *Journal of Clinical Oncology*, **2019**, 37, 1050-1050	2.2	1
50	Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up.. *Journal of Clinical Oncology*, **2019**, 37, 575-575	2.2	1
49	Cell plasticity associated to taxane-resistance in preclinical cell models and in circulating tumor cells from metastatic castration-resistant prostate cancer patients.. *Journal of Clinical Oncology*, **2019**, 37, 238-238	2.2	1
48	The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver		1
47	A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease.. *Journal of Clinical Oncology*, **2021**, 39, 1057-1057	2.2	1
46	High mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. *Clinical Cancer Research*, **2021**,	12.9	1
45	Abstract PD15-01: Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial. *Cancer Research*,	10.1	1
44	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry.. *European Journal of Cancer*, **2022**, 170, 10-16	7.5	1
43	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. *Npj Breast Cancer*, **2021**, 7, 145	7.8	0
42	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211053416	5.4	0
41	Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC) in HR+/HER2- early breast cancer (EBC) patients.. *Journal of Clinical Oncology*, **2015**, 33, 11049-11049	2.2	0
40	Molecular Classification of Breast Cancer **2016**, 203-219		0
39	Determinants of enhanced vulnerability to Covid-19 in U.K. cancer patients: Results from the OnCovid study.. *Journal of Clinical Oncology*, **2021**, 39, 1574-1574	2.2	0
38	The Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms. *Cancer Research*, **2021**, 81, 1540-1551	10.1	0
37	Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease. *Annals of Hematology*, **2021**, 100, 2997-3005	3	0

36	Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A. *Cancer Research*, **2022**, 82, P1-18-03-P1-18-03	10.1	0
35	Abstract P4-10-04: Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy. *Cancer Research*, **2022**, 82, P4-10-04-P4-10-04	10.1	0
34	Abstract PD13-04: Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3). *Cancer Research*, **2022**, 82, PD13-04-PD13-04	10.1	0
33	Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05). *Cancer Research*, **2022**, 82, P4-10-01-P4-10-01	10.1	0
32	Abstract OT2-11-07: Solti-1905. Elacestrant in preoperative setting, a window of opportunity study (ELIPSE trial). *Cancer Research*, **2022**, 82, OT2-11-07-OT2-11-07	10.1	0
31	Abstract OT1-17-01: Solti-1716. Targeting with pembrolizumab + paclitaxel non-luminal by PAM50 hormone receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK4/6 inhibitor treatment (TATEN trial). *Cancer Research*, **2022**, 82, OT1-17-01-OT1-17-01	10.1	0
30	Abstract OT2-27-01: Solti-1718 NEREA Trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched (HER2-E) advanced breast cancer (BC). *Cancer Research* , **2022**, 82, OT2-27-01-OT2-27-01	10.1	0
29	Abstract GS2-00: Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2 advanced breast cancer. *Cancer Research*, **2022**, 82, GS2-00-GS2-00	10.1	0
28	Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies. *Cancer Research*, **2022**, 82, PD2-05-PD2-05	10.1	0
27	Abstract P2-14-13: Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer (SOLTI-1503 PROMETEO): Safety and efficacy interim analysis. *Cancer Research*, **2022**, 82, P2-14-13-P2-14-13	10.1	0
26	Abstract P1-07-02: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC). *Cancer Research*, **2022**, 82, P1-07-02-P1-07-02	10.1	0
25	Abstract OT2-19-03: Solti-1801. Analysis of the efficacy of CDK4/6 inhibitors in combination with hormonal treatment in luminal breast cancer in relation to the intrinsic subtype and markers of immunity (CDK-predict). *Cancer Research*, **2022**, 82, OT2-19-03-OT2-19-03	10.1	0
24	Pertuzumab Use in the Adjuvant Setting: Why Not?. *Journal of Clinical Oncology*, **2017**, 35, 1138	2.2	
23	Response. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	
22	Implementing preoperative endocrine therapy in breast cancer. *Lancet Oncology, The*, **2020**, 21, 1390-1392	12.7	
21	What New in Biology. *Breast*, **2017**, 36, S29	3.6	
20	Response to immunotherapy, platinum-based chemotherapy or their combination in metastatic urothelial carcinoma (MUC) with or without FGFR-3 alterations: Single cohort experience.. *Journal of Clinical Oncology*, **2020**, 38, 560-560	2.2	
19	Association of high plasma glutamine levels with outcome in metastatic castration-resistant prostate (mCRPC) patients treated with taxanes.. *Journal of Clinical Oncology*, **2020**, 38, 164-164	2.2	

18	Association of neuroendocrine (NE) mRNA expression profiling in hormone-sensitive tumors samples with adverse clinical outcome in castration-resistant prostate cancer (CRPC) patients.. *Journal of Clinical Oncology*, **2020**, 38, 165-165	2.2
17	Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. *Frontiers in Immunology*, **2021**, 12, 792609	8.4
16	Validation of CA-125 concentration nadir within the normal range following primary treatment as a predictor of survival for epithelial ovarian cancer (EOC). *Journal of Clinical Oncology*, **2007**, 25, 16007-16007	2.2
15	Different pCR rates according PAM50 defined subtypes in HER2 positive early breast cancer treated with neoadjuvant pertuzumab and trastuzumab.. *Journal of Clinical Oncology*, **2018**, 36, e12634-e12634	2.2
14	Immune-related expression profiles and sunitinib response in metastatic clear cell renal cell carcinoma (ccRCC).. *Journal of Clinical Oncology*, **2018**, 36, e16579-e16579	2.2
13	Association between genotypes, clinical scores and survival outcome in metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2018**, 36, 3553-3553	2.2
12	Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancers.. *Journal of Clinical Oncology*, **2018**, 36, 3076-3076	2.2
11	ARV7 and ARFL mRNA in blood to predict androgen receptor inhibitors and docetaxel response in castration-resistant prostate cancer patients.. *Journal of Clinical Oncology*, **2019**, 37, 207-207	2.2
10	The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as a biomarker of taxane resistance in castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2019**, 37, 235-235	2.2
9	Blinded independent validation of the PAM50-based Chemo-Endocrine Sensitivity Predictor (CESP) in hormone receptor (HR)-positive/HER2-negative (HR+/HER2-) breast cancer following neoadjuvant chemotherapy (NAC).. *Journal of Clinical Oncology*, **2015**, 33, 569-569	2.2
8	High-risk ipilimumab-related diarrhea/colitis: Experience and use of ancillary tests in changing toxicity management.. *Journal of Clinical Oncology*, **2016**, 34, e14552-e14552	2.2
7	Immune gene expression, survival outcome and response to PD-1/PD-L1 blockade: A TCGA pan-cancer analysis.. *Journal of Clinical Oncology*, **2016**, 34, 3033-3033	2.2
6	Protein tyrosine kinase 6 (PTK6, BRK) amplification in HER2+ breast cancer as a mechanism of HER2 resistance.. *Journal of Clinical Oncology*, **2013**, 31, 11021-11021	2.2
5	Abstract P2-15-01: Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis in luminal breast cancer. *Cancer Research*, **2022**, 82, P2-15-01-P2-15-01	10.1
4	Abstract TF2-3: Molecular heterogeneity in HER2+ breast cancer - can outcomes be predicted?. *Cancer Research*, **2022**, 82, TF2-3-TF2-3	10.1
3	Abstract P4-06-08: Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European breast cancer specialists - 1st results of the PROCURE project. *Cancer Research*, **2022**, 82, P4-06-08-P4-06-08	10.1
2	Abstract PD8-03: Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study. *Cancer Research*, **2022**, 82, PD8-03-PD8-03	10.1
1	Abstract OT1-12-01: Solti-1804 HER2-PREDICT: Translational study of tumor samples from breast cancer patients treated with trastuzumab deruxtecan in the metastatic setting. *Cancer Research*, **2022**, 82, OT1-12-01-OT1-12-01	10.1